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Abstract: The use of indirect comparisons to evaluate the relative effectiveness between two 
or more treatments is widespread in the literature and continues to grow each year. Appropri-
ate methodologies will be essential for integrating data from various published clinical trials 
into a systematic framework as part of the increasing emphasis on comparative effectiveness 
research. This article provides a case study example for clinicians using the baseline study 
population characteristics and response rates of the tyrosine kinase inhibitors in imatinib-
resistant or imatinib-intolerant chronic myelogenous leukemia followed by a discussion of 
indirect comparison methods that are being increasingly implemented to address challenges 
with these types of comparisons.
Keywords: comparative effectiveness research, meta-analysis, BCR–ABL-positive chronic 
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Introduction
Health care providers and policy makers routinely rely on available evidence to make 
informed clinical and medical decisions on treatment interventions, whether on clinical 
effectiveness, safety, cost-effectiveness, or quality of life outcomes.
Where existing practice guidelines do not yet exist, data from randomized control 
trials (RCTs) provide the most reliable source for examining the relative effectiveness 
of different interventions. Well-conducted head-to-head RCTs of available treatments 
are generally accepted as the most valid evidence in comparing relative outcomes for 
competing interventions. Moreover, when large amounts of published and unpublished 
data exist, clinicians and health care policy makers often rely on systematic reviews 
or meta-analyses of different treatment options, where large amounts of published and 
unpublished data are synthesized from different clinical studies.
However, pairwise (or more) clinical trials of all eligible treatments for a particular 
indication are not always available or feasible. In many cases, there may be an indica-
tion where several placebo-controlled RCTs for the various treatments are available, 
however no studies in which the treatments have been compared directly with each 
other. Even if direct comparison studies have been conducted, the data may be of poor 
quality and/or insufficient.
Where direct comparative evidence is unavailable or limited, indirect comparisons 
using the available data from well-designed and conducted studies using common 
comparators, such as a placebo, no treatment, or other existing interventions, are 
recommended and may be very useful. While there is still some concern that indirect 





awareness and understanding of the underlying assumptions 
will help support the usefulness of indirect comparisons for 
evaluating competing health care interventions.3,4
Indirect comparisons
Comparisons of treatments not from head-to-head studies 
may come in several different forms; in a simple example, 
trying to compare evidence from separate placebo-controlled 
RCTs for treatment A and treatment B. In this scenario, a com-
parison between treatment A and treatment B is estimated 
relative to the effect of the common comparator, C (ie, the 
placebo-controlled group). In order to minimize bias, the 
baseline study populations in the respective studies should 
ideally be similar, as should the study design and methodol-
ogy, follow-up, and statistical analyses, although adjustment 
to control for any potential differences is possible. In more 
complex situations, known as mixed or multiple treatment 
comparisons, also known as network meta-analysis,5 evidence 
for more than two treatments are compared. Multiple treat-
ment comparisons may also refer to circumstances where 
direct and indirect evidence are combined to strengthen the 
inference regarding the relative treatment effects of two or 
more interventions.6 Whether comparisons are made for 
greater than two interventions, or use both indirect and direct 
comparisons,6,7 awareness of assumptions for examining 
comparisons across multiple studies is critical.
The use of indirect comparisons to evaluate the relative 
effectiveness between two or more treatments is widespread 
in the literature and continues to grow each year. While classic 
frequentist methods are still the most common approach used 
for indirect methods,4 there is an increasing popularity and 
use of approaches such as Bayesian meta-analyses, as seen 
in workshops and courses at scientific meetings, as well as 
in the number of publications in high-tier journals.8
Case study
Background
Imatinib mesylate (Gleevec®/Glivec®; Novartis Pharmaceuti-
cals, Basel, Switzerland) was developed as the first available 
inhibitor with targeted activity against the constitutively 
active tyrosine kinase of the BCR–ABL chimeric fusion 
protein present in patients with chronic myelogenous leu-
kemia (CML), and has become the current standard of care 
for CML due to remarkable long-term activity and a mild 
toxicity profile.9,10
While imatinib is an effective, frontline treatment for 
patients with chronic phase CML, some patients are unable 
to respond to, become resistant to, or are unable to tolerate 
some of the side effects of imatinib, leaving few   treatment 
options available. Second-generation tyrosine kinase 
inhibitors with greater potency and less susceptibility to 
mutation-induced mechanisms of resistance have led the 
way in therapeutic approaches for patients who cannot be 
treated with imatinib.
Nilotinib (Tasigna®; Novartis Pharmaceuticals and 
dasatinib (Sprycel®; Bristol-Myers Squibb, Princeton, NJ) 
were developed as novel targeted therapies to address the 
challenges associated with developed resistance in patients 
treated with imatinib. In clinical trials, treatment with 
nilotinib or dasatinib has achieved strong hematologic and 
cytogenetic response in patients with CML with primary 
or secondary imatinib resistance or imatinib intolerance. 
Currently, no head-to-head studies are available comparing 
nilotinib with dasatinib, although data from single-arm stud-
ies suggest differences in both efficacy and safety between 
the two treatments.
Clinical design differences for tyrosine 
kinase inhibitors
While both nilotinib and dasatinib have been shown to be 
highly effective in chronic phase CML patients with imatinib 
resistance or intolerance, the pivotal investigations of these 
agents11,12 were nonrandomized Phase II studies, making 
direct comparisons difficult. Moreover, the patient popula-
tions and protocols for each study were different, further 
complicating both efficacy and safety comparisons.
Defining imatinib resistance
The approval of dasatinib 70 mg twice daily was based on 
the SRC/ABL Tyrosine Kinase Inhibition Activity Research 
Trial (START-C) Phase II registration study.12 However, more 
recently, a 100 mg once-daily dosing schedule was approved 
for chronic phase CML patients based on results from a 
Phase III dose and schedule optimization (2 × 2) study.13 
Nilotinib was approved based on results of the 2101 trial.11 
These studies used similar definitions of imatinib resistance 
that correspond with the European LeukemiaNet recom-
mendations regarding failure to achieve hematologic and 
cytogenetic milestones or loss of responses,14 with imatinib 
resistance defined as no complete hematologic response by 
three months; no minor cytogenetic response by six months; 
no major cytogenetic response by 12 months; and a loss 
of complete hematologic response or major cytogenetic 
response at any time. However, in the dasatinib Phase III 
dose optimization study, patients who tolerated imatinib 
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response after 12 months and were unable to tolerate   imatinib 
dose escalation to 600 mg/day were still considered to be 
imatinib-resistant. Patients in a partial cytogenetic response 
or major cytogenetic response were thus eligible for the dasa-
tinib dose optimization study. These patients were included 
in the imatinib-resistant population, despite the fact that 
many patients (20% in the 100 mg once-daily arm including 
intolerant patients) entered the study with a baseline major 
cytogenetic response.
There were also differences in the dose and require-
ments for duration of prior imatinib therapy between the 
trials. In the nilotinib trial, imatinib-resistant patients 
were required to have received dose-escalated imatinib 
therapy with $600 mg/day for at least three months prior 
to trial enrollment. In contrast, there were no imatinib 
dose-escalation requirements for enrollment in the dasatinib 
studies.11,12 Of chronic phase CML patients enrolled in the 
2101 study, 72% received imatinib doses $600 mg/day 
(including 38% who received .800 mg/day) as the highest 
prior imatinib dose. For patients in the dasatinib study, 72% 
of patients enrolled reported .600 mg/day prior imatinib 
use, and 37% of patients in the dose optimization 2 × 2 study 
reported $800 mg/day imatinib prior to study enrollment. 
While the criteria between the nilotinib and dasatinib trials 
appear to be balanced with regards to imatinib resistance 
for enrollment, defining highest prior dose and duration of 
imatinib among the studies indicate differences that make 
comparisons challenging. Furthermore, the eligibility of 
patients with suboptimal responses to imatinib in the dasat-
inib 2 × 2 study also make it very difficult to compare efficacy 
data with the 2101 study data.
Defining imatinib intolerance
In the dasatinib START-C trial, imatinib intolerance was 
defined as at least Grade 3 nonhematologic toxicity or 
Grade 4 hematologic toxicity persisting for .7 days related 
to imatinib.12 However, in the dasatinib 2 × 2 study, intoler-
ance was defined as Grade 3 or worse toxicity that led to 
discontinuation of imatinib therapy. Imatinib intolerance 
was defined more stringently in the nilotinib trial, ie, patients 
without an major cytogenetic response and who discontinued 
for persistent Grade 3/4 adverse events despite optimal sup-
portive care, or Grade 2 adverse events related to imatinib 
despite optimal supportive care persisting for $one month, 
or recurring . three times with dose reduction or discon-
tinuation.11 Importantly, imatinib-intolerant patients achiev-
ing a major cytogenetic response following imatinib therapy 
were not eligible for participation in the nilotinib study. 
Overall, 84% of imatinib-intolerant patients enrolled into the 
nilotinib study did not have a major cytogenetic response. 
Of the   imatinib-intolerant patients entering the study with a 
major cytogenetic response, a partial or complete cytogenetic 
response was observed in 40% of patients. These eligibility 
differences resulted in many imatinib-intolerant patients 
with pre-existing major cytogenetic response at study entry, 
ie, 44% of the imatinib-intolerant patients enrolled in the 
dasatinib START-C study and 20% of the patients (including 
some resistant patients) in the dasatinib dose optimization 
2 × 2 study.11,13,15,16 Additionally, 51% of patients treated with 
dasatinib in the dose optimization study had a baseline com-
plete hematologic response upon study entry, compared with 
36% of nilotinib-treated patients in the 2101 study.13,16 Data 
from recent analyses suggest that patients with a complete 
hematologic response have a greater chance of achieving a 
cytogenetic response.16,17
Clinical case study with response rates
Because there are currently no head-to-head studies between 
the two available second generation tyrosine kinase inhibitors, 
clinicians and medical decision-makers looking to examine 
the efficacy evidence from individual studies of nilotinib and 
dasatinib must look at individual studies.
For nilotinib, the key evidence comes from a paper 
published in 2007 by Kantarjian et al.11 This paper followed 
280 patients with chronic phase CML with a median treat-
ment duration of 245 days (eight months).
While initial approval indicated 70 mg twice-daily dos-
ing for chronic phase CML based on the dasatinib START-C 
study,12 in late 2007 new product labeling changed the dosing 
to 100 mg once daily for chronic phase CML based on results 
from the Phase III Dose and Schedule Optimization (2 × 2) 
study reported by Shah et al.13 It is therefore important to 
examine the evidence of the currently recommended dosing 
for dasatinib from this 2 × 2 study rather than that from the 
previous pivotal study. Median duration of treatment was 
eight months.
In the following example, we examine the challenges of 
comparing efficacy evidence from these studies for treat-
ing imatinib-resistant and imatinib-intolerant patients with 
chronic phase CML.
The percentage of patients achieving a major cytogenetic 
response, which was the primary efficacy endpoint in both 
studies with a minimum follow-up of six months, is presented 
in the Table 1. In the pivotal nilotinib study, a major cyto-
genetic response was achieved in 50% of imatinib-resistant 
or imatinib-intolerant patients with chronic phase CML. By OncoTargets and Therapy 2010:3
Table 1 Comparisons of major cytogenetic response rates between nilotinib and dasatinib for imatinib-resistant/intolerant CML
Correction for baseline 
characteristics
Nilotinib 400 mg 
bid (2101)11
Dasatinib 100 mg 
qd (2 × 2)13
Dasatinib 50 mg 
bid (2 × 2)13
Dasatinib 140 mg 
qd (2 × 2)13
Dasatinib 70 mg 
bid (2 × 2)13
n = 291 n = 167 n = 168 n = 167 n = 168
MCyr at study entry 11 (4%)11* 34 (20%) 23 (14%) 28 (17%) 31 (18%)
MCyr at six months 
reported in publications11,13
145 (50%) 98 (59%) 90 (54%) 93 (56%) 93 (55%)
Adjusted MCyR to reflect new 
responders
134 (46%) 64 (38%) 67 (40%) 65 (39%) 62 (37%)
Notes: *As noted in the nilotinib 2101 study:11 “In addition, five patients entered the study with a complete cytogenetic response and maintained their response in the study; 
another three patients entered the study in partial cytogenetic response and also maintained their response in the study; and three patients had missing baseline assessment 
but achieved complete cytogenetic response during the study. Therefore, another 11 (4%) patients had documentation of major cytogenetic response during the study.”
Abbreviations: qd, once daily; bid, twice daily; Mcyr, major cytogenetic response.





comparison, those treated with dasatinib 100 mg once daily, 
the current recommendation for chronic phase CML patients, 
59% of patients achieved a major cytogenetic response. Thus, 
dasatinib 100 mg once daily may appear more effective than 
nilotinib 400 mg twice daily by simply looking at these effi-
cacy rates without regard to differences in study design or 
baseline patient clinical characteristics.
Comparison of response and progression rates over 
time between nilotinib and dasatinib must be considered in 
the context of the study inclusion criteria and the baseline 
characteristics of the patient populations as previously men-
tioned. Of particular note, patients with chronic phase CML 
treated with nilotinib (compared with the dasatinib 100 mg 
once-daily arm in the 2 × 2 dose and schedule optimization 
study) were more heavily pretreated with high-dose ima-
tinib and interferon, less likely to have a baseline complete 
hematologic response or major cytogenetic response, more 
likely to have baseline mutations, and more likely to have 
p-loop mutations.11,13
A quick adjustment of simply removing the patients that 
already were in a major cytogenetic response at the start of 
each respective study indicates substantial changes in response 
rates between the two treatments. Even not taking into account 
any other discrepancies between study and clinical charac-
teristics in disease severity and pretreatment activity between 
patients treated with nilotinib and dasatinib, correcting only 
for baseline major cytogenetic response status demonstrates 
how important homogeneity of study design and patient char-
acteristics are in comparing efficacy rates between different 
treatments. Reflecting those with new responses, dasatinib-
treated CML patients (100 mg once daily) thus had only 38% 
achieving a new major cytogenetic response compared with 
the 46% of nilotinib-treated patients (see Table 1).
While similarity in patient demographics is ideal for 
comparing different treatments, it becomes even more 
important when certain baseline characteristics modify 
the outcome. For example, it has been shown that baseline 
mutation status influences the response rates for efficacy in 
clinical trials of both nilotinib and dasatinib. Patients harbor-
ing baseline mutations had major cytogenetic response rates 
that were 15%–50% lower.13,18–20 Additionally, those with 
baseline mutation rates had a 1.5-fold increased risk of disease 
progression.18,20 Specifically, those with p-loop mutations (ie, 
those falling between amino acids 248–256), are significant 
and may be associated with lower response rates and a faster 
rate of disease progression (eg, E255K/V).11,20
Discussion of methods and Bayesian 
meta-analysis
The example presented above is given to emphasize the 
importance of trial similarity prior to conducting indirect 
comparisons. While the information shown was primarily 
for informal discussion, the actual data from the respective 
nilotinib and dasatinib studies would need to be analyzed 
using more complex methodology. As the studies described 
do not have a common comparator (ie, the nilotinib study was 
a single-arm open-label study, whereas the dasatinib study 
was a 2 × 2 factorial design with four open-label dasatinib 
treatment arms), and there is a significant difference in clini-
cal characteristics between the patients in each respective 
study, only a naïve indirect comparison was possible; simple 
adjusted methods for indirect comparison would not be 
appropriate. While existing second-line studies provide only 
an opportunity for naïve indirect comparisons, new studies 
for first-line treatment using second-generation TKIs in newly 
diagnosed CML have imatinib as a common comparator and 
would thus allow for adjusted indirect comparisons.
Adjusted indirect comparisons can preserve the strength 
of randomization because individual studies are considered 
the units of analysis, and not treated as if they had come 
from one large trial.21,22 They may contain fewer biases than 
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clinical trials if the sets of trials are similarly biased.22 Patient 
baseline clinical characteristics should be similar across the 
different treatment interventions as should the protocols of 
the different trials. However, in reality, there are usually 
significant differences in study and patient characteristics, 
which may or may not be assessed and adjusted for in 
regression models.
Several methodologic challenges in the use of indirect 
comparisons have recently been highlighted by Song et al in 
their survey of the published systematic reviewed literature.4 
Most of these problems surround issues related to assump-
tions of homogeneity underlying the comparisons. The 
validity of adjusted indirect comparisons weighs heavily on 
the internal validity of each study, as well as the similarity 
of the studies with regard to patient population, methodol-
ogy, and analysis.2
Bayesian meta-analysis is one approach available for 
indirect comparisons that can accommodate multiple 
common comparators and/or require less restrictive study 
assumptions and scenarios. Bayesian statistics are increas-
ingly being used in the research community as an important 
method for combining evidence. Rather than focusing on 
a single comparison of two interventions, these methods 
include and treat all included interventions equally.4 Bayes-
ian methods in meta-analysis are useful when homogeneity 
between various studies does not exist, and offer the great-
est flexibility in models evaluating evidence from indirect 
comparisons, particularly in random effects models that 
can account for the heterogeneity of between-trial varia-
tions, and lends itself to a decision framework that supports 
medical decision-making.23–26 Bayesian methods have been 
applied across a variety of therapeutic and disease areas, 
including methicillin-resistant Staphylococcus aureus skin 
infections, hemophilia, malaria, colony stimulating factors, 
drug-eluting stents, hyperlipidemia, and breast cancer.27–33 
Moreover, Bayesian statistics allow pooling of information 
from all relevant studies, whether comparative or single-
arm studies, while adjusting multiple variables and study 
differences. In CML studies, using Bayesian meta-analysis 
methods may minimize bias and provide a meaningful com-
parison of treatment options, while also allowing input on 
a variety of inclusion and external information, including 
prior knowledge of Sokal risk, baseline mutation status, and 
other variables that might help predict treatment success or 
failure in patients with CML.
Bayesian methods for evaluating indirect comparisons 
require more complex statistical techniques, although recent 
developments in software, such as WINBUGS (Bayesian 
inference Using Gibbs Sampling), have made for easier 
implementation of Bayesian methods.34 However, expert 
statistical understanding is still required to appropriately 
use and interpret the data. 
Conclusion
In the context of CML, application of indirect comparison 
methods would be useful and timely. The natural history of 
the disease has been radically changed over the past decade 
and will continue to evolve as newer targeted therapies show 
evidence of effectiveness. As new interventions are developed, 
the number of clinical trials to measure the effectiveness 
and safety of these treatments will also continue to grow. 
Clinicians and policy makers need ways to synthesize the 
increasing amount of evidence generated from such studies, 
especially where competing interventions exist. In the absence 
of head-to-head RCTs of the newer tyrosine kinase inhibitors, 
indirect comparisons, especially advanced techniques such as 
Bayesian meta-analysis, are valuable methodologic tools that 
can provide health care decision makers with useful informa-
tion on the comparative effectiveness of CML therapies.
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